US 12,440,676 B2
Implanted pulse generators with reduced power consumption via signal strength/duration characteristics, and associated systems and methods
Jon Parker, San Jose, CA (US)
Assigned to NEVRO CORP., Redwood City, CA (US)
Filed by Nevro Corp., Redwood City, CA (US)
Filed on Aug. 18, 2023, as Appl. No. 18/452,485.
Application 18/452,485 is a continuation of application No. 17/114,314, filed on Dec. 7, 2020, granted, now 11,766,566.
Application 17/114,314 is a continuation of application No. 16/183,456, filed on Nov. 7, 2018, granted, now 10,881,857, issued on Jan. 5, 2021.
Application 16/183,456 is a continuation of application No. 15/227,821, filed on Aug. 3, 2016, granted, now 10,173,062, issued on Jan. 8, 2019.
Application 15/227,821 is a continuation of application No. 14/710,375, filed on May 12, 2015, granted, now 9,409,020, issued on Aug. 9, 2016.
Claims priority of provisional application 62/000,985, filed on May 20, 2014.
Prior Publication US 2024/0173549 A1, May 30, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/36 (2006.01); A61N 1/37 (2006.01)
CPC A61N 1/36071 (2013.01) [A61N 1/36125 (2013.01); A61N 1/36171 (2013.01); A61N 1/36175 (2013.01); A61N 1/3708 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method of programming a signal generator to provide stimulation therapy to a patient, the method comprising:
programing the signal generator to, in response to a determination that an available voltage is insufficient to deliver an electrical signal at a target therapy amplitude and a target signal delivery parameter, (a) determine an updated therapy amplitude and an updated signal delivery parameter based on pre-established correlations for similarly situated patients, and (b) deliver therapy to the patient using the updated amplitude and signal delivery parameter, wherein the signal delivery parameter includes a pulse width and/or a duty cycle.